– USA, CA – Coherus Biosciences, Inc. (Nasdaq: CHRS), today announced the appointment of cancer immunotherapy leader Dr. Jill O’Donnell-Tormey (Ph.D.) to its Board of Directors.
“I am excited to welcome Dr. Jill O’Donnell-Tormey to the Coherus Board of Directors. Under her leadership and strategic direction, the Cancer Research Institute has grown to play a key role across the changing landscape of cancer immunology, pioneering and driving advancements in the field. Jill’s experience and insights will be a perfect complement to our Board as we continue to advance the development of innovative cancer immunotherapies and build a leading immuno-oncology franchise,” said CEO, Denny Lanfear.
Dr. O’Donnell-Tormey will also serve on the Nominating and Corporate Governance Committee.
About Coherus BioSciences
Dr. O’Donnell-Tormey is CEO and Director of Scientific Affairs of the Cancer Research Institute, a nonprofit organization dedicated exclusively to advancing immunotherapy to treat, control, and cure all cancers. She joined the organization in 1987 and has been CEO since 1993. As a recognized leader and advocate for cancer immunotherapy, Dr. O’Donnell-Tormey has spearheaded programs at CRI designed to identify and advance promising combination immunotherapies as well as facilitate global coordination of clinical research initiatives across academia and industry.
Dr. O’Donnell-Tormey serves on the boards of The City University of New York, Richmond University Medical Center, and the Staten Island Foundation.
“Translating promising science into cancer treatments that can change patients’ lives is at the core of CRI’s mission. Next-generation immuno-oncology agents and combinations can take us to the next stage of significantly improved outcomes for patients,” said Dr. O’Donnell-Tormey. “I am excited to join the Coherus Board of Directors and to help the company advance its goal of delivering new immuno-oncology medicines to patients.”
Dr. O’Donnell-Tormey served as a research associate in the department of medicine at Cornell University Medical College and as a postdoctoral fellow in the laboratory of cellular physiology and immunology at The Rockefeller University. She holds a Doctor of Philosophy in cell biology from the SUNY Downstate Medical Center and earned a Bachelor of Science in chemistry from Fairleigh Dickinson University.
About Coherus BioSciences
Coherus is a commercial-stage biopharmaceutical company building a leading immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved products. In 2021, Coherus in-licensed toripalimab, an anti-PD-1 antibody, in the United States and Canada. Coherus plans to resubmit a BLA for toripalimab for the treatment of advanced nasopharyngeal carcinoma by mid-summer 2022. Toripalimab is also being evaluated in pivotal clinical trials for the treatment of rare and highly prevalent cancers.
Coherus markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The FDA is currently reviewing the biologics license application for CIMERLI, a biosimilar of Lucentis, with a target action date of August 2022.
For more information: https://www.coherus.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.